Quick Answer
BridgeBio Pharma, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $502.08 million for the year ending 2025.
- BridgeBio Pharma, Inc. showed an increase of +126.3% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from BridgeBio Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), BridgeBio Pharma, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 1,137.9%.
- Historical annual values: Fiscal year 2025: $502.08 million | Fiscal year 2024: $221.90 million | Fiscal year 2023: $9.30 million | Fiscal year 2022: $77.65 million | Fiscal year 2021: $69.72 million | Fiscal year 2020: $8.25 million | Fiscal year 2019: $40.56 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: